Compare BKU & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | ZLAB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.0B |
| IPO Year | 2011 | 2017 |
| Metric | BKU | ZLAB |
|---|---|---|
| Price | $45.79 | $17.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $42.92 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 1.0M | 827.4K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 44.85 | N/A |
| EPS | ★ 3.54 | N/A |
| Revenue | ★ $1,016,093,000.00 | $441,629,000.00 |
| Revenue This Year | $14.68 | $30.20 |
| Revenue Next Year | $5.73 | $34.71 |
| P/E Ratio | $13.00 | ★ N/A |
| Revenue Growth | 10.45 | ★ 24.14 |
| 52 Week Low | $28.21 | $17.72 |
| 52 Week High | $46.56 | $44.34 |
| Indicator | BKU | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 71.78 | 15.69 |
| Support Level | $44.71 | $19.40 |
| Resistance Level | $46.92 | $18.67 |
| Average True Range (ATR) | 0.91 | 0.54 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 71.28 | 5.35 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.